IAA
ALNY icon

Independent Advisor Alliance’s Alnylam Pharmaceuticals ALNY Stock Holding History

Independent Advisor Alliance’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$530K Buy
1,602
+997
+165% +$339K 0.01% 1093
2025
Q4 		$241K Sell
605
-74
-11% -$32.7K 0.01% 873
2025
Q3 		$310K Buy
+679
New +$276K 0.01% 761

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Independent Advisor Alliance's ALNY Position: Q1 2026 in Review

Independent Advisor Alliance increased its Alnylam Pharmaceuticals (ALNY) stake by 165% in Q1 2026, buying an estimated $339K and bringing the position to 1,602 shares worth $530K. The position accounts for 0.01% of the portfolio, ranked #1093.

Independent Advisor Alliance first reported a position in ALNY in Q3 2025 and has held it in 3 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Independent Advisor Alliance held 1,602 shares of Alnylam Pharmaceuticals worth $530K as of Q1 2026.
  • Independent Advisor Alliance bought 997 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $339K.
  • Alnylam Pharmaceuticals made up 0.01% of Independent Advisor Alliance's portfolio in Q1 2026, its #1093 holding.
  • Independent Advisor Alliance first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Independent Advisor Alliance's 13F filing for Q1 2026, filed 12 May 2026.